Fecha de registro: 14 sept 2021


The global antifibrinolytic drugs market was valued at $13,593 million in 2018 and is expected to reach $19,333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic drugs are used to prevent fibrinolysis or lysis of blood clots or thrombus. Fibrinolysis is a process in which stimulated plasminogen removes excess fibrin to promote fibrin clot formation and wound healing. Further, tissue plasminogen activators and other plasminogen activators are the first line mediators in lysis therapy. Blockers of fibrinolysis act when plasminogen is converted to plasmin, by reversely blocking the lysine binding sites of plasmin or by active inhibition of plasmin via serine protease inhibition.

Read more

Artificial Saliva Market


Más opciones